We hypothesize that the preferred use of etanercept in the treatment of SJS/TEN over more recent anti-TNF-α medications is down to lack of availability of such biologics in earlier trials, when the medication was first being trialled. This evidence concerns the gene TNF and Schwartz-Jampel syndrome.